Richard James Hill
Direktor/Vorstandsmitglied bei BLACKWALL LIMITED
Vermögen: 5 Mio $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Jessica Glew | F | - | 13 Jahre | |
| Michael Frank | M | - |
Caring for Montanans, Inc.
 Caring for Montanans, Inc. Managed Health CareHealth Services Caring for Montanans, Inc. provides health insurance products and services. It serves the residents and businesses of Montana. The company was founded in 1986 and is headquartered in Helena, MT. | - |
| Timothy Brown | M | - | 16 Jahre | |
| Joseph Glew | M | - | - | |
| Katherine Woodthorpe | M | - |
INSEARCH Ltd.
| 24 Jahre |
| Mark A. Burzynski | M | - |
Caring for Montanans, Inc.
Caring for Montanans, Inc. Managed Health CareHealth Services Caring for Montanans, Inc. provides health insurance products and services. It serves the residents and businesses of Montana. The company was founded in 1986 and is headquartered in Helena, MT. | - |
| Nicholas John Victor Geddes | M | - | 13 Jahre | |
| Agata Ryan | F | - | 1 Jahre | |
| Robin Tedder | M | - | - | |
| Paul Ronald Bell | M | 76 |
Aviragen Therapeutics, Inc.
 Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA.
Westmead Millennium Institute for Medical Research
| 2 Jahre |
| Randall Olsen | M | - |
Caring for Montanans, Inc.
Caring for Montanans, Inc. Managed Health CareHealth Services Caring for Montanans, Inc. provides health insurance products and services. It serves the residents and businesses of Montana. The company was founded in 1986 and is headquartered in Helena, MT. | - |
| Eric L. Schindler | M | - |
Caring for Montanans, Inc.
Caring for Montanans, Inc. Managed Health CareHealth Services Caring for Montanans, Inc. provides health insurance products and services. It serves the residents and businesses of Montana. The company was founded in 1986 and is headquartered in Helena, MT. | - |
| Fred Olson | M | - |
Caring for Montanans, Inc.
Caring for Montanans, Inc. Managed Health CareHealth Services Caring for Montanans, Inc. provides health insurance products and services. It serves the residents and businesses of Montana. The company was founded in 1986 and is headquartered in Helena, MT. | - |
| Paul Grmoljez | M | - |
Caring for Montanans, Inc.
Caring for Montanans, Inc. Managed Health CareHealth Services Caring for Montanans, Inc. provides health insurance products and services. It serves the residents and businesses of Montana. The company was founded in 1986 and is headquartered in Helena, MT. | - |
| Larry A. Viano | M | 69 |
Caring for Montanans, Inc.
Caring for Montanans, Inc. Managed Health CareHealth Services Caring for Montanans, Inc. provides health insurance products and services. It serves the residents and businesses of Montana. The company was founded in 1986 and is headquartered in Helena, MT. | - |
| Paul Tresidder | M | - | - | |
| Jerry E. Lusk | M | - |
Caring for Montanans, Inc.
Caring for Montanans, Inc. Managed Health CareHealth Services Caring for Montanans, Inc. provides health insurance products and services. It serves the residents and businesses of Montana. The company was founded in 1986 and is headquartered in Helena, MT. | - |
| Frederick Hirschy | M | - |
Caring for Montanans, Inc.
Caring for Montanans, Inc. Managed Health CareHealth Services Caring for Montanans, Inc. provides health insurance products and services. It serves the residents and businesses of Montana. The company was founded in 1986 and is headquartered in Helena, MT. | - |
| Chase Hibbard | M | - |
Caring for Montanans, Inc.
Caring for Montanans, Inc. Managed Health CareHealth Services Caring for Montanans, Inc. provides health insurance products and services. It serves the residents and businesses of Montana. The company was founded in 1986 and is headquartered in Helena, MT. | - |
| Larry Gianchetta | M | - |
Caring for Montanans, Inc.
Caring for Montanans, Inc. Managed Health CareHealth Services Caring for Montanans, Inc. provides health insurance products and services. It serves the residents and businesses of Montana. The company was founded in 1986 and is headquartered in Helena, MT. | - |
| Nora Gerrity | M | - |
Caring for Montanans, Inc.
Caring for Montanans, Inc. Managed Health CareHealth Services Caring for Montanans, Inc. provides health insurance products and services. It serves the residents and businesses of Montana. The company was founded in 1986 and is headquartered in Helena, MT. | - |
| Dean Folkvord | M | - |
Caring for Montanans, Inc.
Caring for Montanans, Inc. Managed Health CareHealth Services Caring for Montanans, Inc. provides health insurance products and services. It serves the residents and businesses of Montana. The company was founded in 1986 and is headquartered in Helena, MT. | - |
| Lane Basso | F | - |
Caring for Montanans, Inc.
Caring for Montanans, Inc. Managed Health CareHealth Services Caring for Montanans, Inc. provides health insurance products and services. It serves the residents and businesses of Montana. The company was founded in 1986 and is headquartered in Helena, MT. | - |
| Jimmie Ashcraft | M | - |
Caring for Montanans, Inc.
Caring for Montanans, Inc. Managed Health CareHealth Services Caring for Montanans, Inc. provides health insurance products and services. It serves the residents and businesses of Montana. The company was founded in 1986 and is headquartered in Helena, MT. | - |
| Sharon Archambeault | F | - |
Caring for Montanans, Inc.
Caring for Montanans, Inc. Managed Health CareHealth Services Caring for Montanans, Inc. provides health insurance products and services. It serves the residents and businesses of Montana. The company was founded in 1986 and is headquartered in Helena, MT. | - |
| Ewoud Jacobus Kulk | M | 77 |
Westmead Millennium Institute for Medical Research
| - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Russell H. Plumb | M | 65 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | - |
| James Fox | M | 73 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 6 Jahre |
| Joseph Patti | M | 60 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 6 Jahre |
| Donald Bayly | M | - | 4 Jahre | |
| Anthony Stephen Dijanosic | M | - | 5 Jahre | |
| Geoffrey F. Cox | M | 80 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 12 Jahre |
| Darren Smith | M | 58 | 11 Jahre | |
| Jeffery Errington | M | 68 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 3 Jahre |
| Peter J. Azzarello | M | 53 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 3 Jahre |
| John Allan Eady | M | 78 | - | |
| Glen T. Hickey | M | - | 5 Jahre | |
| Caroline Raw | F | - | 1 Jahre | |
| Angela Leard Axisa | F | 48 | 3 Jahre | |
| Neville Mitchell | M | 65 | 1 Jahre | |
| Gilman E. Wong | M | 72 | - | |
| David Cade | M | 55 | 14 Jahre | |
| Gordon Geoffrey Marsden Smith | M | 71 | 6 Jahre | |
| Nicholas George Kirk | M | 62 | - | |
| Michael Dougherty | M | 66 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 5 Jahre |
| Andrew McLean | M | - | 2 Jahre | |
| Grant F. Latta | M | - | 5 Jahre | |
| Anne VanLent | F | 76 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | - |
| Jack Theseus Lowenstein | M | 67 | 14 Jahre | |
| John P. Richard | M | 66 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | - |
| Alexander Whitelum | M | - | 3 Jahre | |
| Maurice William Loomes | M | 76 | 14 Jahre | |
| John Ian Messenger | M | 78 | 7 Jahre | |
| Stuart Ernest Nicholas Brown | M | - | - | |
| Helen Kurincic | F | - | - | |
| Dimi Boubolas | F | - | - | |
| Ron Kocak | M | - |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | - |
| Vivienne Green | F | - | - | |
| Donna Fort | F | - | 9 Jahre | |
| Kevin Richardson | M | - | - | |
| Sophie Gowland | F | - | 3 Jahre | |
| Ralph Peters | M | - | 15 Jahre | |
| Tony Thomas | M | - | 1 Jahre | |
| Craig Ulrick | M | - | 1 Jahre | |
| Michael Mangano | M | - | - | |
| Robert Hardie | M | - | - | |
| David James | M | - | 5 Jahre | |
| Uday Patel | M | - |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | - |
| Anna Novotney-Barry | F | - |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | - |
| Hamish McKellar | M | - | - | |
| Ian Mabbutt | M | - | 7 Jahre | |
| Anthony Vincent Connon | M | 73 | 7 Jahre | |
| Peter Chapman E. Cook | M | 77 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 1 Jahre |
| John Reginald Grant | M | - | 8 Jahre | |
| Ian Gust | M | - |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | - |
| Charles Barrie Whattam | M | - | 4 Jahre | |
| Adrian Ross Diggelmann | M | - | 7 Jahre | |
| John H. Vernachio | M | - |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | - |
| Burwood Chew | M | - | 4 Jahre | |
| Ian Keith Crow | M | 75 | 12 Jahre | |
| Barbara June Gibson | F | - | 12 Jahre | |
| Raafat E. F. Fahim | M | 70 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 1 Jahre |
| Marius van den Berg | M | - | - | |
| Robert F. Walliser | M | - | 4 Jahre | |
| Peter A. Bailey | M | - | 5 Jahre | |
| Jim Pappas | M | - | - | |
| Henk Tissing | M | - | 8 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Australien | 51 | 58,62% |
| Vereinigte Staaten | 33 | 37,93% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Richard James Hill
- Persönliches Netzwerk
